Cytokines and MDS

  • Krishnan Allampallam
  • Vilasini T. Shetty
  • Azra Raza
Part of the Cancer Treatment and Research book series (CTAR, volume 108)


Myelodysplastic syndromes (MDS) are considered to be stem cell disorders. A number of cytogenetic abnormalities have been demonstrated in these patients. In the last decade it has become apparent that besides the cytogenetic and molecular abnormalities at the individual cell level, the global alterations of the bone marrow (BM) microenvironment brought about by shifts in the cytokine milieu may play a crucial role in defining the pathobiology of these disorders. The combination of factors produced by adherent stromal cells and hematopoietic cells constitute the web of cytokines meshing a variety of biological processes including survival, proliferation and differentiation of the hematopoietic cells. Imperatively thus, hematopoiesis in these patients is a result of a critical balance between the stimulatory and inhibitory signals transduced by these cytokines. Primarily effects of these cytokines could be chemotatic, stimulatory or inhibitory to hematopoiesis.


Aplastic Anemia Myelodysplastic Syndrome Granulocyte Macrophage Colony Stimulate Factor Hematopoietic Growth Factor Flt3 Ligand 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allampallam K, Shetty V, Dar S, Hussaini S, Cartilidge J, Broderick E, Townsend W, Qawi H, Mazzoran L, Mahamood W, Mundle S, Reza S, Gundroo A, Yakoob L, Robinson L, Preisler H & Raza A. (1997) Elevated levels of serum tumor necrosis factor receptors in myelodysplastic syndromeBlood92, Abst. # 1743, 422a.Google Scholar
  2. Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang R & Raza A (1999). Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes.Anticancer Research19,5323–5328.PubMedGoogle Scholar
  3. Allampallam K, Shetty V, Broady Robinson L, Hussaini S., Broderick E, Mundle S, Reddy P, Dar S, Zaidi A, Nascimben F & Raza A (2000). The clinical and biological significance of apoptosis, macrophages and cytokines in 145 patients with myelodysplastic syndromes.Blood96,Abst # 1550, 359a.Google Scholar
  4. Akoi I, Higashi K, Homori M, Chikazawa H & Ishikawa K. (1990). Responsiveness of bone marrow erythrrpoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rhEP) in vitro in aplastic anemia and myelodysplastic syndrome.American Journal Hematology35, 6–12.CrossRefGoogle Scholar
  5. Aul C, Arming M, Runde V & Schneider W (1991) Serum erythropoietin concentrations in patients with myelodysplastic syndromes.Leukemia Research15, 571–575.PubMedCrossRefGoogle Scholar
  6. Birg F, Rosnet O, Carbuccia N & Birnbaum D.(1994). The expression of FMS, Kit and Flt3 inGoogle Scholar
  7. hematopoietic malignancies.Leukemia and Lymphoma13, 223–227Google Scholar
  8. Bouscary, D., de Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F., & Fontenay-Roupie, M. (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.Leukemia11, 839–845..PubMedCrossRefGoogle Scholar
  9. Cebon JS & Morstyn G (1990). The potential role of granulocyte macrophage colony stimulating factor (GM-CSF) in cancer chemotherapy. Cancer Survey, 9, 131–155.Google Scholar
  10. Colombat PH, Renouos M, Lamagnere JP & Renous G (1988). Immunologic indices in myelodysplastic syndromes.Cancer61, 1075–1081.PubMedCrossRefGoogle Scholar
  11. Dinarello CA. (1991). Interleukin-I and interleukin-1 antagonismBlood77,1627–1652.PubMedGoogle Scholar
  12. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M & Mitter W (1995). Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.British Journal of Haematology91, 403–408.PubMedCrossRefGoogle Scholar
  13. Filipowicz AW, Lynman SD, Gratwohl A, Tichelli A, Speck B & Nissen C (1996). Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood,88,4493–5599.Google Scholar
  14. Gancer A & Hoelzer D (1992). Treatment of myelodysplastic syndromes iwht hematopoietic growth factors.Hematology Oncology Clinics of North America6, 633–653.Google Scholar
  15. Gersuk, G.M., Beckham, C., Loken, M.R., Kiener, P., Anderson, J.E., Ferrand, A., Troutt, A.E., Ledbetter, J.A., & Deeg, H.J. (1998) A role for tumor necrosis factor-a, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome.British Journal of Haematology103, 176–188.PubMedCrossRefGoogle Scholar
  16. Herold M, Schmalz] R & Swierzina H (1992). Increased serum interleukin 6 levels in patients with myelodysplastic syndrome, Leukemia Research, 16, 585–588.PubMedCrossRefGoogle Scholar
  17. Jacobsen SEW, Jacobsen FW, Fahlman C and Austen LS (1994). TNF-a, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis.Stem Cells, 12, 11 1–128.Google Scholar
  18. Jacobs A, Janawska-Wieczorek A, Caro J, Bowen DT, Lewis T (1989). Circulating erythropoietin in patients with myelodysplastic syndromes.British Journal of Haematology73,36–39.PubMedCrossRefGoogle Scholar
  19. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kawiyama R, & Hirokawa K. (1997). Overexprcssion of tumor necrosis factor (TNF)- alpha and interferon gamma by bone marrow cells from patients with myelodysplastic syndromes.Leukemia11, 2049–2054.PubMedCrossRefGoogle Scholar
  20. Krueger GRF, Kudlimay D, Ramon A, Klyepperlbert U & Schumacher K (1994). Demonstration of active and latent Epstein-Barr virus and human herpes virus-6 infections in bone marrow cells of patients with myelodysplastic and chronic myeloproliferative diseases.In Vivo8,533–542.PubMedGoogle Scholar
  21. Misago M, Kikuchi M, Tsukada J, Hanamura T, Kamachi S, Eto S. (1991). Serum levels of GCSF, M-CSF and GM-CSF in a patient with cyclic neutropenia.American Journal of Hematology37, 312–313.Google Scholar
  22. Miyahara M, Shimamoto Y, Yamada H, Shibata K & Matsuzaki K O. (1997) Cytomegalovirusassociated myclodysplasia and thrombocytopenia in an immunocompetent adult.Annals of Hematology74, 99–101.PubMedCrossRefGoogle Scholar
  23. Mundle, S., Venugopal, P., Cartlidge, J., Pandav, D., Broady-Robinson, L., gezer, S., Robin, E., Rifkin, S., Klein, M., Alston, D., Hernandez, B., Rosi, D., Alvi, S., Shetty, V., Gregory, S., & Raza, A. (1996) Indication of an involvement of interleukin-lb converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes (MDS).Blood88, 2640–2647.PubMedGoogle Scholar
  24. Mundle S, Allampallam K, Rashid KA, Dangerfield B, Cartlidge J, Zeitler D, Afenya E, Alvi S, Shetty V, Venugopal P & Raza A. (2001) Presence of activation-related m-RNA for EBV and CMV in the bone marrow of patients with myelodysplastic syndromesCancer Letters164, 197–205.PubMedCrossRefGoogle Scholar
  25. Qadir K, Bokhari SAJ, Miller MA, Siegrist C, Bismayer J & Raza A. (1992) In situ localization of Transforming growth factor beta and S-phase cells in patients with acute myeloid leukemia and myelodysplastic syndrome.AntiCancer Research12,403–408.PubMedGoogle Scholar
  26. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Riflcin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S & Preisler H.(1995a). Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.Blood86, 268–276.Google Scholar
  27. Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Dameron S, Wright V, Adler S, Loew J, Schoot S, Ali N & Preisler H. (1995) Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastic reveals extensive apoptosis as the probable basis for ineffective hematopoiesis.American Journal of Hematology48,143–154.PubMedCrossRefGoogle Scholar
  28. Raza A (1998a) Hypothesis: myelodysplastic syndromes may have a viral etiology.International Journal of Hematology68, 245–256.CrossRefGoogle Scholar
  29. Raza A (1998b) Initial transforming even in myelodysplastic syndromes may be viral: case for cytomegalovirus.Medical Oncology15, 166–173.CrossRefGoogle Scholar
  30. Sallerfors B & Olofsson T (1991). Granulocyte-macrophave colony stimulating factor (GMCSF) and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia.British Journal of Haematology78, 343–351.PubMedCrossRefGoogle Scholar
  31. Shetty V, Allampllam K, Hussaini S, Ali A, Mundle S, Akhtar A, Cartlidge J, Mativi B, Qawi H, Venugopal P&Raza A (1998). Absence of 1113 ligand correlates with high incidence of apoptosis in myelodysplastic syndrome (MDS)Proceedings of American Association of Cancer Research39, 142–143, abstr# 973.Google Scholar
  32. Shetty V., Hussaini S., Borady-Robinson L, Gao X, Dar S, Mundle S, Cartlidge J, Bagai K, Showel M, Andrews C, Akhtar A, Ali A, Mativi BY, Venugopal P, Chopra H, Bi S, Gregory SA, Preisler H and Raza A. (1997) Suppression of tumor necrosis factor —alpha (TNF-a) induced apoptosis by Flt-3 ligand in myelodysplastic syndromes (MDS) and HL-60 cells.Blood90, 203a, abstr # 894.Google Scholar
  33. Shetty, V., Mundle, S., Alvi, S., Showel, M., Broady-Robinson, L., Dar, S., Borok, R., Showel, J., Gregory, S., Rifkin, S., Gezer, S., Parcharidou, A., Venugopal, P., Shah, R., Hernandez, B., Klein, M., Alston, D., Robin, E., Dominguez, C. & Raza, A. (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.Leukemia Research20, 891–900.PubMedCrossRefGoogle Scholar
  34. Verhoef GEG, Schowwer DP, Ceuppens JL, Damme JV, Goossens W & Boogaerts MA (1992). Measurement of serum cytokine levels in patients with myelodysplastic syndromes.Leukemia6,1268–1272.PubMedGoogle Scholar
  35. Watari K, Asano S, Shirafuiji J, Kodo H, Ozawa K, Takaku F. & Kamanchi S, (1989). Serum granulocyte colony stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay.Blood73,117–122.PubMedGoogle Scholar
  36. Zwierzina H, Anderson JE., Holzinger RI, Storb TB, Nuessler V & Lyman SD (1999). Endogenous Flt-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes.Leukemia13, 553–557.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Krishnan Allampallam
    • 1
  • Vilasini T. Shetty
    • 1
  • Azra Raza
    • 1
  1. 1.MDS Center and Section of Myeloid Diseases, Department of MedicineRush UniversityChicago

Personalised recommendations